Japanese HCV-Infected Patients Met SVR with Daclatasvir, Asunaprevir
Healio reported on a phase 3 trial of two antiviral drugs for treating chronic hepatitis C virus (HCV) genotype 1b infection. In a multiclinical trial, Japanese researchers tested dual therapy with daclatasvir and asunaprevir to treat 222 patients (median age 62.5 years; 65.3 percent women) with chronic HCV 1b who were not successful with previous therapies. The researchers separated participants into two groups, with 135 individuals forming the interferon-ineligible/intolerant group and 87 nonresponders. Participants received 60 milligrams (mg) daclatasvir once daily and 100 mg asunaprevir twice a day for 24 weeks.
Results show that 87.4 percent of participants in the interferon-ineligible/intolerant group achieved sustained virologic response (SVR) at 24 weeks and 89.6 percent completed therapy. In the nonresponder group, 80.5 percent experienced SVR and 83.9 percent completed treatment. Of each group, 14 patients dropped out due to adverse effects, lack of efficacy, or at personal request; 5.9 percent of all patients experienced serious adverse effects.
The researchers concluded that the 24-week ribavirin-free all-oral treatment using daclatasvir and asunaprevir showed high rates of SVR in these participants with HCV genotype 1b.
The full report, “Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection,” was published in the journal Hepatology (2014; 59(6): 2083–2091; doi: 10.1002/hep.27113).
Date of Publication
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.